The value of positron emission tomography (PET) lies in its unsurpassed high-sensitivity for tracking biomarkers and molecular processes in vivo; however, it lacks the ability of multiplexing signals from more than one radiotracer thus limiting the amount of information available after each scan. We have developed a new technology compatible with any existing PET system, that enables simultaneous imaging of two radio tracers in a single PET acquisition. We accomplished this by combining a radiotracer labeled with a standard positron-emitting radionuclide with another labeled with a radionuclide emitting prompt γ-rays together with the positrons. Recovered images from simultaneous dual-tracer PET acquisitions were comparable to those obtained in sequential single tracer scans, allowing the identification and quantification in-vivo of several interlinked disease markers in a single acquisition
Related work
Triple coincidences in positron emission tomography (PET) are events in which three γ-rays are detected simultaneously. These events, though potentially useful for enhancing the sensitivity of PET scanners, are discarded or processed without special consideration in current systems, because there is not a clear criterion for assigning them to a unique line-of-response (LOR). We have developed several novel strategies to use these type of events in PET including multiplexed PET imaging, enhance the sensitivity of the scanner or improve image quality when using non-standard positron emitting radionuclides.
Related work
Small animal imaging is an important tool in several disciplines such as drug development and translational cancer research. The most significant among the clear advantages of imaging is that functional information at the molecular and cellular levels can be measured in an intact, living system. During his stage in the Medical Imaging Lab of the Gregorio Maranon Hopsital (IISGM) Dr Lage developed several of these systems including complete PET, PECT/CT and SPECT systems for rodent imaging.
Related links
There is a critical need for tools that increase the accessibility of eye care to address the most common cause of vision impairment: uncorrected refractive errors. Due to the global shortage of eye care professionals, it is often difficult, particularly in low-resource settings, to obtain accurate prescriptions for eyeglasses that would effectively correct refractive errors and restore good vision. At MEDIC we have developed together with PlenOptika Inc. (MA, USA) and Aurolab (India) an innovative device that addresses this massive problem by significantly simplifying and speeding up the refraction process for prescribing eyeglasses.
SimVis will have a major clinical impact in the field of presbyopia corrections, as it holds potential to change the way these corrections are prescribed: This technology allows the patient for first time to experience the real world through multifocal corrections before surgery, so the patients can decide what correction will fit better their expectations before intra-ocular lens implantation. MEDIC is helping to develop this Technology in collaboration with the VioBio Lab (Instituto de Optica Daza de Valdes, CSIC, Spain) and the Spin-off Company 2EyesVision.